QIAGEN N.V. announced solid financial results for the second quarter of 2025 on August 5, 2025, exceeding its outlook for both net sales and adjusted earnings. Net sales rose 7% to $534 million compared to Q2 2024, with 6% growth at constant exchange rates (CER), surpassing the outlook for at least 5% CER growth.
Core sales, excluding discontinued products, also rose 6% CER. The adjusted operating income margin increased 1.5 percentage points to 29.9% of sales, driven by efficiency gains despite the impact of new tariffs. Adjusted diluted EPS was $0.60, or $0.62 CER, exceeding the outlook for at least $0.60 CER.
Based on this strong performance, QIAGEN increased its full-year 2025 net sales outlook to 4-5% CER growth (from prior ~4% CER) and 5-6% CER core sales growth (from prior ~5% CER). The adjusted diluted EPS target was reaffirmed at approximately $2.35 CER, and the adjusted operating income margin target remains at about 30%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.